{ "meta": { "data_length": 1, "message": "Statement id stmt:ema:tafinlar:4:1 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Atafinlar%3A4%3A1", "status": "success", "status_code": 200, "timestamp_elapsed": 0.002099, "timestamp_received": "2026-10-16T22:57:50.613432+00:00Z", "timestamp_returned": "2026-10-16T22:57:50.615531+00:00Z", "trace_id": "cd32b878-a155-4fbc-ba14-93b7536a27b8" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:ema:tafinlar:4:1", "type": "Statement", "description": "The European Medicines Agency (EMA) has authorized dabrafenib in combination with trametinib for the adjuvant treatment of adult and adolescent patients aged 12 years and older with Stage III melanoma with a BRAF V600 variant, following complete resection.", "contributions": [ { "id": "ctrb:ema:2026-04-30:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2026-04-30", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } }, { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:ema:tafinlar", "type": "Document", "documentType": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "title": null, "aliases": [], "description": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised May 2026. Accessed August 2, 2026.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Europharm Limited.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Tafinlar", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "dabrafenib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2013-09-18", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2026-05-19", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:90", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C3224", "conceptType": "Disease", "name": "Melanoma", "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:oncotree:MEL", "code": "MEL", "name": "Melanoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Melanoma+%28MEL%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C3224", "code": "C3224", "name": "Melanoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3224" ] } }, "objectTherapeutic": { "id": "txgrp:18", "membershipOperator": "AND", "therapies": [ { "id": "tx:ncit:C82386", "conceptType": "Therapy", "name": "Dabrafenib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1424911", "code": "1424911", "name": "dabrafenib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1424911" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:43532299", "code": "43532299", "name": "dabrafenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/43532299" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "B-RAF inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C82386", "code": "C82386", "name": "Dabrafenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386" ] } }, { "id": "tx:ncit:C77908", "conceptType": "Therapy", "name": "Trametinib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1425099", "code": "1425099", "name": "trametinib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1425099" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:43532497", "code": "43532497", "name": "trametinib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/43532497" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "MEK inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C77908", "code": "C77908", "name": "Trametinib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908" ] } } ] }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:17", "present": true, "subject": { "id": "bmkr:17", "type": "CategoricalVariant", "name": "BRAF p.V600K", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.pfWn9x9oFBRzGda1xXcOrE-BrX0R__N8", "type": "Allele", "name": "NP_004324.2:p.Val600Lys", "aliases": [ "NP_004324.2:p.V600K", "BRAF p.V600K" ], "description": "VRS variation of NP_004324.2:p.Val600Lys", "digest": "pfWn9x9oFBRzGda1xXcOrE-BrX0R__N8", "expressions": [ { "syntax": "hgvs.p", "value": "NP_004324.2:p.Val600Lys", "extensions": [ { "name": "hgvs.p_short", "value": "p.V600K" } ] } ], "location": { "id": "ga4gh:SL.t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 600 of the Refseq protein NP_004324.2, which is the protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6).", "digest": "t-3DrWALhgLdXHsupI-e-M00aL3HgK3y", "sequenceReference": { "id": "ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "type": "SequenceReference", "name": "NP_004324.2", "aliases": [ "ensembl:ENSP00000288602.6", "ga4gh:SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "refseq:NP_004324.2" ], "description": "The protein product of the MANE Select coding transcript for BRAF (refseq:NM_004333.6), corresponding to the Refseq protein accession NP_004324.2.", "moleculeType": "protein", "refgetAccession": "SQ.cQvw4UsHHRRlogxbWCB8W-mKD4AraM9y", "residueAlphabet": "aa" }, "start": 599, "end": 600, "sequence": "V" }, "state": { "type": "LiteralSequenceExpression", "sequence": "K" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:1097", "conceptType": "Gene", "name": "BRAF", "primaryCoding": { "id": "coding:hgnc:1097", "code": "HGNC:1097", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000157764", "code": "ENSG00000157764", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000157764" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:673", "code": "673", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/673" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_004333.6", "code": "NM_004333.6", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "7" }, { "name": "start_position", "value": 140453136 }, { "name": "end_position", "value": 140453137 }, { "name": "reference_allele", "value": "AC" }, { "name": "alternate_allele", "value": "TT" }, { "name": "cdna_change", "value": "c.1798_1799GT>AA" }, { "name": "protein_change", "value": "p.V600K" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 15 }, { "name": "rsid", "value": "rs121913227" }, { "name": "hgvsg", "value": "7:g.140453136_140453137delinsTT" }, { "name": "hgvsc", "value": "ENST00000288602.6:c.1798_1799delinsAA" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:ema:tafinlar:4", "type": "Indication", "description": "Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult and adolescents aged 12 years and older with Stage III melanoma with a BRAF V600 mutation, following complete resection.", "contributions": [ { "id": "ctrb:ema:2026-04-30:0", "type": "Contribution", "description": "Indication received approval from the European Commission.", "date": "2026-04-30", "contributor": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." } }, { "id": "ctrb:vanallenlab:2024-10-20:0", "type": "Contribution", "description": "Adding EMA approvals for use to database", "date": "2024-10-20", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:ema:tafinlar", "type": "Document", "documentType": "Regulatory approval", "name": "Tafinlar (dabrafenib) [product information]. EMA.", "title": null, "aliases": [], "description": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised May 2026. Accessed August 2, 2026.", "urls": [ "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:ema", "type": "Agent", "agentType": "organization", "name": "European Medicines Agency", "description": "Regulatory agency that approves medicines for use in the European Union." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Europharm Limited.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Tafinlar", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "dabrafenib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2013-09-18", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2026-05-19", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }